Merck To Seek Prostate Cancer Claim For Proscar Despite Short Patent Life
Executive Summary
Merck intends to file a supplemental NDA for Proscar (finasteride) based on results from the National Cancer Institute's Prostate Cancer Prevention Trial
You may also be interested in...
GSK's Avodart To Get Panel Review For Prostate Cancer Prevention, With Merck's Proscar Along For The Ride
FDA's Oncology Drugs Advisory Committee will review Merck's Proscar (finasteride) as well as GlaxoSmithKline's Avodart (dutasteride), even though Merck has not filed an sNDA.
GSK Oncology Pipeline Expansion Means Healthy Phase III Program In ’06
GlaxoSmithKline's strategy of building its oncology business is paying off with a range of new chemical entities entering Phase III development within the next year for cancer-related indications, executives said during an oncology R&D update in New York
GSK Oncology Pipeline Expansion Means Healthy Phase III Program In ’06
GlaxoSmithKline's strategy of building its oncology business is paying off with a range of new chemical entities entering Phase III development within the next year for cancer-related indications, executives said during an oncology R&D update in New York